EUCTR2005-001656-21-FI
Active, not recruiting
Not Applicable
A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator in adults following tonsillectomy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Postoperative pain following tonsillectomy
- Sponsor
- Grünenthal GmbH
- Enrollment
- 450
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female subjects aged 18 65 years inclusive at enrolment and study entry
- •2\. ASA classification I\-II
- •3\. Planned bilateral tonsillectomy due to recurrent acute tonsillitis or chronic tonsillitis
- •4\. Anesthesiological and surgical procedures performed according to the protocol
- •5\. Moderate to severe postoperative pain at rest on 4 point VRS and a pain intensity at rest of minimum 4 on 11 point\-NRS within 4 hours following the end of the anesthesia
- •6\. Negative urine abuse test at the enrolment visit and pre operative examination. Subjects who declare that they are receiving benzodiazepines for medical purposes may participate even if they test positive.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •1\. Pregnancy or breastfeeding mother
- •2\. Evidence or history of neurotic personality, psychiatric illness, epilepsy or suicide risk
- •3\. Women of childbearing potential who does not use satisfactory contraception (i.e. double barrier, hormonal or IUD method) 28 days prior to enrolment visit, during the study and until 28 days after the follow\-up visit.)
- •4\. History of chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C within the post 3 months. History of AIDS
- •5\. Poor medical status (e.g. NYHA class \= 3; child classification for hepatic impairment \>A (Pugh et al., 1973\); decompensated chronic obstructive pulmonary disease) or, at the discretion of the investigator, clinical signs that raise concerns about subject’s suitability for the study
- •6\. Creatinine higher than 1\.5X upper limit of normal range
- •7\. ALT and/or AST higher than 3X upper limit of normal range
- •8\. At enrolment ECG with findings which could impact operability or any planned study procedure: e.g. marked repolarization abnormality (e.g. suspicious or definite congenital long QT syndrome) and/or QT values of: QTCB females \= 450 msec, QTCB males \= 430 msec, uncorrected QT \= 500 msec
- •pre\-operative ECG with findings which could impact operability or any planned study procedure
- •9\. Known contraindications/hypersensitivity to the comparator tramadol and rescue medication acetaminophen or diclofenac
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator in adults following tonsillectomyPostoperative pain following tonsillectomyMedDRA version: 8.0Level: LLTClassification code 10054711EUCTR2005-001656-21-GBGrünenthal GmbH
Active, not recruiting
Phase 1
A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator in adults following tonsillectomyEUCTR2005-001656-21-CZGrünenthal GmbH450
Active, not recruiting
Not Applicable
A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator in adults following tonsillectomyEUCTR2005-001656-21-HUGrünenthal GmbH450
Active, not recruiting
Phase 1
Dose-ranging study of nemolizumab in atopic dermatitisEUCTR2016-005025-37-PLGALDERMA R&D, SNC351
Active, not recruiting
Phase 1
Dose-ranging study of nemolizumab in atopic dermatitisEUCTR2016-005025-37-FRGALDERMA R&D, SNC250